美股期權個股詳情

IQV241220C110000

添加自選

0.00
0.000.00%

延時15分鐘行情收盤價 11/26 09:30 (美東)

0.00最高價0.00最低價

艾昆緯股票討論

登錄發表評論

areecep

06/07 02:52

Final Trades: Amazon, Goldman Sachs, AbbVie and IQVIA Holdings

$巴菲特持倉 (LIST2999.US)$ $伯克希爾-A (BRK.A.US)$ $伯克希爾-B (BRK.B.US)$ $亞馬遜 (AMZN.US)$ $艾伯維公司 (ABBV.US)$ $艾昆緯 (IQV.US)$ $高盛 (GS.US)$

https://www.youtube.com/watch?v=_GqAmT6nEIU

來自YouTube

Moomoo AI

03/07 05:08

Insiders' substantial share sale, especially by W. Staub and Constantinos Panagos, may worry shareholders. The lack of insider purchases over the past year could be a negative sign. Yet, high insider ownership might indicate well-aligned management incentives with shareholders.

Trade Alert: President of Research & Development Solutions Of IQVIA Holdings W. Staub Has Sold Stock

Divided Sky

02/14 07:10

$艾昆緯 (IQV.US)$ Aced the numbers again in a very competitive market

Moomoo AI

02/06 08:30

The market's opinion of the business has improved over the past five years, likely due to consistent earnings growth. Despite recent sell-offs, if fundamentals suggest sustainable long-term growth, this could be a worthwhile opportunity.

Those Who Invested in IQVIA Holdings (NYSE:IQV) Five Years Ago Are up 60%

Moomoo AI

01/07 06:29

IQVIA Holdings is currently undervalued and has a bright future. Its growth hasn't been fully factored into the share price. It may be a great time to increase holdings or enter the stock.

At US$221, Is It Time To Put IQVIA Holdings Inc. (NYSE:IQV) On Your Watch List?

Moomoo AI

2023/12/07 11:46

Insiders selling shares, even below current price, hint they may deem shares not cheap. Coupled with no insider buying, this may serve as a warning to potential investors. High insider ownership, but recent sale history of IQVIA Holdings insiders could raise concern.

IQVIA Holdings Insiders Sell US$6.6m Of Stock, Possibly Signalling Caution

Moomoo AI

2023/10/17 02:29

Bio-Rad Laboratories is likely to maintain an 80% market share in digital PCR products due to extensive offering and embracing continuous investment. Bio-Techne's extensive product offerings and the growth of its analytical instruments business are likely to drive its growth. For IQVIA, sales growth is primarily expected from managing its existing backlog.

Bio-Rad, IQVIA, Bio-Techne Among Top Picks at Credit Suisse

逍遥投资派

2023/07/17 11:14

$艾昆緯 (IQV.US)$营收5年来保持增长，平均增速为8.2%，营业利润受费用增长过快影响在2020年下滑8.1%，其余4年保持增长，5年平均增速为19%，净利润受所得税影响非常大，税前利润2021年暴增2倍，2022年增长21%。
2023Q1营收增长2.4%，营业利润下滑2.8%，净利润下滑11%，高增速似乎要停止了。
目前市盈率38.9，市盈率TTM略增到39.9，考虑到近期增速下滑，可以多观察几个季度。

Moomoo Breakfast US

2023/02/05 19:53

專欄 What to Expect in the Week Ahead (Powell Speaks; DIS, PYPL and UBER Earnings)

Fourth-quarter earnings season continues this week, with close to 90 $標普500指數 (.SPX.US)$ companies scheduled to report. So far, earnings are down about 3% from the same period a year ago, per Refinitiv.
$西蒙地產 (SPG.US)$, $Take-Two互動軟體件 (TTWO.US)$, and $泰森食品 (TSN.US)$ report on Monday, followed by $英國石油 (BP.US)$, $杜邦 (DD.US)$, and $皇家加勒比郵輪 (RCL.US)$.
$迪士尼 (DIS.US)$, $西維斯健康 (CVS.US)$, and ...

Analysts Notebook

2022/11/17 06:57

專欄 US Top Rating Updates on 11/17: TGT, EL, ICE, IQV and More

Target Upgraded to Overweight From Neutral at Piper Sandler
Piper Sandler analyst Edward Yruma upgraded $塔吉特 (TGT.US)$ to Overweight from Neutral with a price target of $200, up from $190. The company has had a difficult 2022, but we are approaching "trough" EBIT margins and the stock's valuation now "looks compelling," Yruma tells investors in a research note.
Canaccord Starts Estee Lauder With Hold, Sees Estimate Risk
Canaccord analys...

暫無評論